Research: T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection
JANUARY 2023: Researchers from SATVI have published results from a study using cutting edge-technology to identify new targets for novel TB vaccine candidates.
The final analysis of a multi-site medical trial involving the University of Cape Town (UCT) has produced the first signal of a potentially effective vaccine against tuberculosis (TB) in almost 100 years.
Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy
The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.Read more
News from the South African Tuberculosis Vaccine Initiative.
SATVI Director, Prof Mark Hatherill will be speaking at the UN High Level Meeting on TB, New York. He will speak at a panel discussion on Friday 22 September 2023 at 21H00 (South African Time) and 15h00 (Central American time).Read more
Research: Assay for Differential Leukocyte Counting and Immunophenotyping in Cryopreserved Ex vivo whole blood (DLC-ICE)
Drs. Imbratta, Gela, Assoc Prof Nemes publish new assay enabling quantifying absolute counts & frequencies of leukocyte subsets & measure expression of activation, phenotypic & functional markers in fixed and cryopreserved whole blood.Read more
Research: Integrated analysis of whole blood oxylipin and cytokine responses after bacterial, viral, and T cell stimulation reveals new immune networks
Professor Tom Scriba,Drs.Munyaradzi Musvosi, Nicole Bilek co-authored "Integrated analysis of whole blood oxylipin & cytokine responses after bacterial,& viral, & Tcell stimulation reveals new immune networks" appearing in iScience Journal.Read more
No vacancies found
On World TB Day, the University of Cape Town (UCT) shines the spotlight on phase three of a clinical trial led by clinicians at the South African Tuberculosis Vaccine Initiative (SATVI).
The corporate history of the South African Tuberculosis Vaccine Initiative is available online. This history is the result of more than 20 interviews conducted over a period of about one year with SATVI staff and students, including ma
The SATVI Annual Report 2021 is available for download.
The University of Cape Town is leading international research into the only licensed TB vaccine, Bacille Calmette-Guerin (BCG), according to a new study.
27 November 2023
(Ends 2 December 2023)More info
SATVI's Professor Tom Scriba will be a speaker at the International Congress of Immunology (IUIS), which will take place in Cape Town from November 27 to December 2, 2023.